Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

PTC Therapeutics, Inc. (PTCT) had Revenue of $1.18B for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$1.18B
Net Income	$866.56M
Cost of Goods Sold	$12.86M
Gross Profit	$1.16B
Operating Expenses	$205.87M
Operating Income	$970.23M
Non-Operating Income/Expense	$-40.40M
Pre-Tax Income	$929.83M
Normalized Pre-Tax Income	$929.83M
Income after Taxes	$866.56M
Income from Continuous Operations	$866.56M
Consolidated Net Income/Loss	$866.56M
Normalized Income after Taxes	$866.56M
EBIT	$970.23M
EBITDA	$975.43M
Weighted-Average Shares Outstanding (Basic)	78.12M
Weighted-Average Shares Outstanding (Diluted)	86.39M
Earnings per Share (EPS) (Basic)	$11.09
Earnings per Share (EPS) (Diluted)	$10.04
Balance Sheet Financials
Current Assets	$2.32B
Property, Plant, and Equipment	$59.46M
Long-Term Assets	$338.98M
Total Assets	$2.66B
Current Liabilities	$595.39M
Long-Term Debt	$2.15B
Long-Term Liabilities	$2.25B
Total Liabilities	$2.84B
Common Equity	$-185.76M
Tangible Shareholders Equity	$-386.55M
Shareholders Equity	$-185.76M
Common Shares Outstanding	79.22M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$870.10M
Cash Flow from Investing Activities	$-184.36M
Cash Flow from Financial Activities	$9.41M
Beginning Cash	$795.32M
End Cash	$1.50B
Increase/Decrease in Cash	$700.55M
Stock-Based Compensation	$18.06M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.89
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.09
Debt to Equity Ratio	-12.94
Gross Margin	98.91%
Operating Margin	82.50%
EBIT Margin	82.50%
EBITDA Margin	--
Pre-Tax Profit Margin	79.06%
Profit Margin	73.68%
Free Cash Flow	$868.45M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.44
Inventory Turnover	0.59
Receiveable Turnover	5.59
Days Sales in Receivables	16.11
Return on Equity	-466.50%
Return on Tangible Equity	-224.18%
Return on Assets	32.63%
Return on Investments	44.12%
Book Value Per Share	$-2.34
Free Cash Flow per Share	$10.05
Operating Cash Flow per Share	$10.07

Data from Zacks Investment Research, Inc.